Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AltaRex and Dompe establish OvaRex alliance for Europe

Nov. 28, 2000

Schering and MediGene begin HPV vaccine trial

Nov. 23, 2000

European Commission grants orphan drug status to Mylotarg for treatment of AML

Nov. 16, 2000

Potential cellular mechanism for adverse cardiac effects of Herceptin described at AHA sessions

Nov. 16, 2000

Independent safety board recommends continuation of Theratope vaccine phase III trial

Nov. 15, 2000

York Medical acquires Norelin from Biostar

Nov. 14, 2000

Data presented at Heat Shock Proteins symposium support clinical application of HspE7

Nov. 10, 2000

First phase III trial of HspE7 commences in anal dysplasia

Nov. 9, 2000

Update on worldwide phase III trials of Maxamine

Nov. 9, 2000

Maxamine protects against IL-2 toxicity in murine model

Nov. 8, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...